76
|
Alcala N, Mangiante L, Poret A, Gabriel A, Derks J, Moonen L, Boyault S, Le Stang N, Ghantous A, Tabone-Eglinger S, Damiola F, Blay J, Mckay J, Dingemans A, Speel E, Caux C, Girard N, Lantuejoul S, Dayton T, Sallé FG, Fernandez-Cuesta L, Foll M. OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
77
|
Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis K, Bakker N, Thakrar B, Taylor A, Feliciano J. Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.044] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
78
|
Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 2019; 10:3407. [PMID: 31431620 PMCID: PMC6702229 DOI: 10.1038/s41467-019-11276-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 07/02/2019] [Indexed: 02/06/2023] Open
Abstract
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.
Collapse
|
79
|
Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C. Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz067.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
80
|
Girard N, Mornex F, Christoph D, Fietkau R, Filippi A, Field J, Garrido Lopez P, McDonald F, Peters S, Klein A, Licour M, Garassino M. PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz067.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
81
|
Marchal T, Royer-Garabige V, Raynard B, Girard N. Impact du statut nutritionnel sur l’efficacité et la tolérance du NIVOLUMAB dans les cancers broncho-pulmonaires. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
82
|
Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol 2019; 30:161-165. [PMID: 30624547 DOI: 10.1093/annonc/mdy553] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
|
83
|
Hochmair M, Morabito A, Hao D, Yang C, Soo R, Yang J, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T, Girard N. Afatinib suivi d’osimertinib en vie réelle chez des patients avec CBNPC avancé EGFR muté : étude GioTag. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
84
|
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes M, Moran S, Castro De Moura M, Davalos V, Piñeyro D, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin M, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga L, Gil-Bazo I, Baraibar I, Lozano M, Varela M, Ruffinelli J, Ramon P, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez A, Fraga M, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile J, Rosell R, Brambilla E, Esteller M. Prédiction épigénétique du bénéfice clinique avec les anti-PD-1 dans le traitement des cancers du poumon non à petites cellules avancées : une étude internationale multicentrique rétrospective. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
85
|
Dingemans A, Hendriks L, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuejoul S, Edwards J, O'Brien M, Reck M, Smit E, Van Schil P, Postmus P, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti G, Senan S, Paz-Ares L, Guckenberger M, Mcdonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Besse B, Novello S. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.530] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
86
|
Girard N. GR01.04 Medical Oncology. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
87
|
Brindel A, Althakfi W, Barritault M, Bringuier PP, Watkin E, Maury JM, Girard N, Brevet M. Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
88
|
Levy A, Hendriks L, Berghmans T, Faivre-Finn C, Giaj Levra M, Giaj-Levra N, Hasan B, Girard N, Greillier L, Lantuejoul S, Edwards J, O’Brien M, Reck M, Besse B, Novello S, Dingemans A. MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.529] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
89
|
Girard N, Cozzone D, de Léotoing L, Tournier C, Vainchtock A, Tehard B, Cortot A. Extra-cost of brain metastases in patients with non-squamous non-small cell lung cancer (NSCLC): A French national hospital database analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
90
|
Felip E, Brahmer J, Broderick S, Swanson S, Awad M, Mitsudomi T, Girard N, Kerr K, Spicer J, Cai J, Yang R, Forde P. P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1478] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
91
|
Girard N, Corona R, Chung J, Millis S, Gay L, Elvin J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Killian J, Ali S, Schrock A, Miller V, Ross J. Recurrent and metastatic carcinomas of the lacrimal gland: High frequency of ERBB2 driven disease. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
92
|
Tuleasca C, Najdenovska E, Régis J, Witjas T, Girard N, Champoudry J, Faouzi M, Thiran JP, Bach Cuadra M, Levivier M, Van De Ville D. Pretherapeutic functional neuroimaging predicts tremor arrest after thalamotomy. Acta Neurol Scand 2018; 137:500-508. [PMID: 29315459 DOI: 10.1111/ane.12891] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/08/2017] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Essential tremor (ET) represents the most common movement disorder. Drug-resistant ET can benefit from standard stereotactic procedures (deep brain stimulation or radiofrequency thalamotomy) or alternatively minimally invasive high-focused ultrasound or radiosurgery. All aim at same target, thalamic ventro-intermediate nucleus (Vim). METHODS The study included a cohort of 17 consecutive patients, with ET, treated only with left unilateral stereotactic radiosurgical thalamotomy (SRS-T) between September 2014 and August 2015. The mean time to tremor improvement was 3.32 months (SD 2.7, 0.5-10). Neuroimaging data were collected at baseline (n = 17). Standard tremor scores, including activities of daily living (ADL) and tremor score on treated hand (TSTH), were completed pretherapeutically and 1 year later. We further correlate these scores with baseline inter-connectivity in twenty major large-scale brain networks. RESULTS We report as predictive three networks, with the interconnected statistically significant clusters: primary motor cortex interconnected with inferior olivary nucleus, bilateral thalamus interconnected with motor cerebellum lobule V2 (ADL), and anterior default-mode network interconnected with Brodmann area 103 (TSTH). For all, more positive pretherapeutic interconnectivity correlated with higher drop in points on the respective scores. Age, disease duration, or time-to-response after SRS-T were not statistically correlated with pretherapeutic brain connectivity measures (P > .05). The same applied to pretherapeutic tremor scores, after using the same methodology described above. CONCLUSIONS Our findings have clinical implications for predicting clinical response after SRS-T. Here, using pretherapeutic magnetic resonance imaging and data processing without prior hypothesis, we show that pretherapeutic network(s) interconnectivity strength predicts tremor arrest in drug-naïve ET, following stereotactic radiosurgical thalamotomy.
Collapse
|
93
|
Tuleasca C, Najdenovska E, Régis J, Witjas T, Girard N, Champoudry J, Faouzi M, Thiran JP, Bach Cuadra M, Levivier M, Van De Ville D. Cover Image. Acta Neurol Scand 2018. [DOI: 10.1111/ane.12945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
94
|
Lafitte C, Mastroianni B, Mornex J, Girard N. Intégration précoce des soins de support en oncologie thoracique, étude rétrospective. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
95
|
Robain M, Pérol M, Girard N, Debieuvre D, Coudert B, Madroszyk A, Gervais R, Besse B, Chomy F, Durando X, Schott R, Cailliot C, Simon G, Beghdad F, Chouaid C. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
96
|
Oselin K, Girard N, Adamsom A, Lepik K, Vanakesa T, Almre I, Leismann T, Chalabreysse L. PUB054 Pathological Discrepancies in the Diagnosis of Thymic Malignancies: The Tallinn-Lyon Experience. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
97
|
Mace P, Milh M, Girard N, Sigaudy S, Quarello E. [How to deal with a fetal head circumference lower than the third percentile?]. ACTA ACUST UNITED AC 2017; 45:491-511. [PMID: 28870427 DOI: 10.1016/j.gofs.2017.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 07/17/2017] [Indexed: 11/29/2022]
Abstract
The prenatal finding of a head circumference (HC) below the 3rd percentile (p) remains, in the same way as short femur or increased nuchal translucency with normal karyotype, one the most difficult situations for the praticionner in the setting of prenatal diagnosis. Microcephaly is a gateway to possible cerebral pathologies, but the main objective is to identify serious prenatal situations. A standardized HC measurement, the use of adapted reference tools and charts, longitudinal following of cephalic biometrics in high-risk situations, and systematic central nervous system analysis can increase the diagnostic performance of ultrasound which is often disappointing for microcephaly. The early distinction between associated or isolated microcephaly makes it possible to quickly orient the prenatal management and counseling. Fetal MRI and genetic counseling are fundamental in this context, making it possible to specify at best the etiological diagnosis and to provide assistance to the neuropediatrician in the establishment of an often uncertain prognosis. The recent increase in cases of microcephaly concomitant with the epidemic of the ZIKA virus is an additional argument to improve our practices and the daily apprehension of HC<3rd p.
Collapse
|
98
|
Girard N, Audigier Valette C, Cadranel J, Monnet I, Hureaux J, HILGERS W, Fauchon E, Fabre E, Besse B, Brun P, Coëtmeur D, Quoix E, Mourlanette P, Barlesi F, Bordenave-Caffre S, Egenod T, Missy P, Morin F, Moro-Sibilot D, Molinier O. IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
99
|
Giaj Levra M, Menis J, Luciani A, De Maio E, Hasan B, Berghmans T, Massiani M, De Waele M, Dingemans AM, Donckele J, Faivre-Finn C, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Tryfonidis K, Wildiers H, Besse B, Novello S. Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): Results from an EORTC pan-European survey. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
100
|
Stahl JP, Azouvi P, Bruneel F, De Broucker T, Duval X, Fantin B, Girard N, Herrmann JL, Honnorat J, Lecuit M, Mailles A, Martinez-Almoyna L, Morand P, Piroth L, Tattevin P. Guidelines on the management of infectious encephalitis in adults. Med Mal Infect 2017; 47:179-194. [PMID: 28412044 DOI: 10.1016/j.medmal.2017.01.005] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 02/06/2023]
|